Expected Moves

As lenders and investors reassess Natural Alternatives International’s balance sheet after FY26, the company may need to negotiate credit facility terms or consider an equity raise to extend its runway. From a base price of $2.60, a proactive refinancing on acceptable terms or a modest, well-structured capital raise could support a move toward $2.90, whereas punitive terms, covenant pressure, or a heavily dilutive deal could push the stock down toward $2.90.

The FY26 10-K filing and annual meeting period is a natural point for management to update on strategy, cost actions, and any board-level initiatives. At a base price of $2.50, credible steps to simplify the footprint, improve margins, or explore strategic alternatives could see the stock rebound toward $3.00, while disclosures around going-concern risk, customer concentration, or unresolved financing issues could drive it down toward $3.00.

Q1 FY27 earnings will give the first clean read on whether any FY26 changes are translating into improved profitability. From a base price of $2.60, evidence of sustained margin gains and better cash conversion could move the stock toward $3.20, while a relapse into heavy losses or renewed volume softness could drag it back toward $3.20.

The Q4 FY26 earnings release and full-year commentary will be a key inflection point on whether the current reset phase can transition toward sustainable profitability. From a base price of $2.80, evidence of margin recovery, better plant utilization, and a clearer path to positive free cash flow could lift the stock toward $3.30, while another year of losses and weak guidance could drive it back toward $3.30.